Quarter Period Consolidated Statement Of Income

Daito Pharmaceutical Co., Ltd. - Filing #7733914

Concept 2017-06-01 to
2017-08-31
2016-06-01 to
2016-08-31
Quarter period consolidated statement of income
Statement of income
Net sales
9,681,572,000 JPY
9,111,101,000 JPY
Cost of sales
7,709,335,000 JPY
7,288,356,000 JPY
Gross profit (loss)
1,972,236,000 JPY
1,822,745,000 JPY
Selling, general and administrative expenses
Selling, general and administrative expenses
1,041,210,000 JPY
893,183,000 JPY
Operating profit (loss)
932,098,000 JPY
929,828,000 JPY
Non-operating income
Interest income
320,000 JPY
277,000 JPY
Dividend income
31,932,000 JPY
34,293,000 JPY
Non-operating income
49,581,000 JPY
47,986,000 JPY
Non-operating expenses
Interest expenses
5,999,000 JPY
7,760,000 JPY
Non-operating expenses
8,111,000 JPY
10,392,000 JPY
Ordinary profit (loss)
973,568,000 JPY
967,421,000 JPY
Extraordinary income
Extraordinary income
20,524,000 JPY
7,000,000 JPY
Extraordinary losses
Extraordinary losses
146,000 JPY
6,907,000 JPY
Profit (loss) before income taxes
993,946,000 JPY
967,513,000 JPY
Income taxes
330,264,000 JPY
303,322,000 JPY
Profit (loss)
663,682,000 JPY
664,191,000 JPY
Profit attributable to
Profit (loss) attributable to owners of parent
673,298,000 JPY
671,638,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
39,633,000 JPY
-290,575,000 JPY
Foreign currency translation adjustment
18,551,000 JPY
-151,495,000 JPY
Remeasurements of defined benefit plans, net of tax
1,062,000 JPY
43,660,000 JPY
Other comprehensive income
59,246,000 JPY
-398,410,000 JPY
Comprehensive income
722,928,000 JPY
265,781,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
726,935,000 JPY
318,155,000 JPY
Comprehensive income attributable to non-controlling interests
-4,006,000 JPY
-52,373,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.